Michael C. Milone, M.D., Ph.D.
Philadelphia, PA 19104
B.S (Chemical Biology)
Stevens Institute of Technology, 1993.
M.D. (Medical Doctor)
UMDNJ- New Jersey Medical School, 1999.
Ph.D (Experimental Pathology/ Immunology)
UMDNJ - Graduate School of Biomedical Sciences, 1999.
Description of Research ExpertiseResearch in my laboratory is focused on T cell biology and applications of genetically-engineered T cells to the treatment of disease. Active research projects in my laboratory include:
1) Developing chimeric antigen receptors (CARs) for adoptive immunotherapy of cancer with enhanced function and improved safety.
2) Developing and applying synthetic immunoreceptors to the treatment of immune-mediated disease.
3) Exploring the role of co-stimulatory signals in directing T cell metabolism and the way this metabolism affects T cell function within tumors.
Description of Clinical ExpertiseClinical Laboratory Toxicology, Therapeutic Drug Monitoring, Clinical Chemistry, Blood Banking/Transfusion Medicine, Therapeutic Apheresis
Selected PublicationsGarfall Alfred L, Dancy Ehren K, Cohen Adam D, Hwang Wei-Ting, Fraietta Joseph A, Davis Megan M, Levine Bruce L, Siegel Don L, Stadtmauer Edward A, Vogl Dan T, Waxman Adam, Rapoport Aaron P, Milone Michael C, June Carl H, Melenhorst J Joseph: T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. Blood advances 3(19): 2812-2815, Oct 2019.
Sellmyer MA, Richman SA, Lohith K, Hou C, Weng CC, Mach RH, O'Connor RS, Milone MC, Farwell MD: Imaging CAR T Cell Trafficking with eDFHR as a PET Reporter Gene. Mol Therapy in press, Oct 2019.
Feins Steven, Kong Weimin, Williams Erik F, Milone Michael C, Fraietta Joseph A: An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. American journal of hematology 94(S1): S3-S9, May 2019.
Thibodeaux Suzanne R, Milone Michael C: Immunotherapy Using Chimeric Antigen Receptor-Engineered T Cells: A Novel Cellular Therapy with Important Implications for the Clinical Laboratory. Clinical chemistry 65(4): 519-529, April 2019.
Cohen Adam D, Garfall Alfred L, Stadtmauer Edward A, Melenhorst J Joseph, Lacey Simon F, Lancaster Eric, Vogl Dan T, Weiss Brendan M, Dengel Karen, Nelson Annemarie, Plesa Gabriela, Chen Fang, Davis Megan M, Hwang Wei-Ting, Young Regina M, Brogdon Jennifer L, Isaacs Randi, Pruteanu-Malinici Iulian, Siegel Don L, Levine Bruce L, June Carl H, Milone Michael C: B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. The Journal of clinical investigation 130: 2210-2221, Mar 2019.
Garfall AL, Stadtmauer EA, Hwang WT, Lacey SF, Melenhorst JJ, Krevvata M, Carroll MP, Matsui WH, Wang Q, Dhodapkar MV, Dhodapkar K, Das R, Vogl DT, Weiss BM, Cohen AD, Mangan PA, Ayers EC, Nunez-Cruz S, Kulikovskaya I, Davis MM, Lamontagne A, Dengel K, Kerr ND, Young RM, Siegel DL, Levine BL, Milone MC, Maus MV, June CH.: Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight 4(4): pii: 127684, February 2019.
Ghassemi Saba, Nunez-Cruz Selene, O'Connor Roddy S, Fraietta Joseph A, Patel Prachi R, Scholler John, Barrett David M, Lundh Stefan M, Davis Megan M, Bedoya Felipe, Leferovich John, Lacey Simon F, Levine Bruce L, Grupp Stephan A, June Carl H, Melenhorst J Joseph, Milone Michael C: Reducing Ex Vivo Culture Improves the Anti-leukemic Activity of Chimeric Antigen Receptor (CAR)-T Cells. Cancer immunology research Page: In Press, Jul 2018.
Milone Michael C, O'Doherty Una: Clinical use of lentiviral vectors. Leukemia 32(7): 1529-1541, Jul 2018.
Laetsch Theodore W, Maude Shannon L, Milone Michael C, Davis Kara L, Krueger Joerg, Cardenas Ana Maria, Eldjerou Lamis K, Keir Christopher H, Wood Patricia A, Grupp Stephan A: False-positive results following lentiviral-based tisagenlecleucel therapy with select HIV-1 NAT methods. Blood 131(23): 2596-2598, Jun 2018.
De-xiu Bu, Reshma Singh, Eugene E. Choi,*, Marco Ruella, Selene Nunez- Cruz, Keith G. Mansfi eld, Paul Bennett, Nathanial Barton, Qilong Wu, Jiquan Zhang, Yongqiang Wang, Lai Wei, Shawn Cogan, Tucker Ezell, Shree Joshi, Kellie J. Latimer, Brian Granda, William R. Tschantz, Regina M. Young, Heather A. Huet, Celeste J. Richardson and Michael C. Milone: Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma. Oncotarget 9(40): 25764-25780, May 2018.